Modulation of Immunologic Response by Preventive Everolimus Application in a Rat CPB Model

[1]  J. Kellum,et al.  Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations. , 2015, Journal of veterinary emergency and critical care.

[2]  G. Vilahur,et al.  Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor , 2014, Front. Physiol..

[3]  G. Junge,et al.  The role of everolimus in liver transplantation , 2014, Clinical and experimental gastroenterology.

[4]  A. Lichtenberg,et al.  A cardiopulmonary bypass with deep hypothermic circulatory arrest rat model for the investigation of the systemic inflammation response and induced organ damage , 2014, Journal of Inflammation.

[5]  M. White,et al.  Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation , 2014, Cellular and Molecular Immunology.

[6]  G. Semenza,et al.  Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart , 2013, Proceedings of the National Academy of Sciences.

[7]  R. Hall.  Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. , 2013, Journal of cardiothoracic and vascular anesthesia.

[8]  J. Dieleman.  Corticosteroids for the inflammatory response to cardiopulmonary bypass: an update. , 2013, Current pharmaceutical design.

[9]  J. Mathew,et al.  Degree of hypothermia in aortic arch surgery - optimal temperature for cerebral and spinal protection: deep hypothermia remains the gold standard in the absence of randomized data. , 2013, Annals of cardiothoracic surgery.

[10]  Y. V. Bayrakova,et al.  Perioperative Dynamics of TLR2, TLR4, and TREM-1 Expression in Monocyte Subpopulations in the Setting of On-Pump Coronary Artery Bypass Surgery , 2013, ISRN inflammation.

[11]  C. Ensor,et al.  Proliferation signal inhibitor toxicities after thoracic transplantation , 2013, Expert opinion on drug metabolism & toxicology.

[12]  B. Nashan,et al.  Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature , 2012, Transplantation.

[13]  D. Schrijvers,et al.  Everolimus Triggers Cytokine Release by Macrophages: Rationale for Stents Eluting Everolimus and a Glucocorticoid , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[14]  G. Pasterkamp,et al.  The innate immune response in reperfused myocardium. , 2012, Cardiovascular research.

[15]  E. Chuluyan,et al.  Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia–reperfusion injury in a rat syngenic kidney transplantation model , 2012, Clinical and experimental immunology.

[16]  A. Yoshimura,et al.  IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. , 2011, International immunology.

[17]  O. McCarty,et al.  S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. , 2011, Blood.

[18]  V. Chopra,et al.  Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. , 2011, The American journal of medicine.

[19]  E. D. de Vries,et al.  Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. , 2011, The oncologist.

[20]  R. Hirose,et al.  Donor pre-treatment with everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant model. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  H. Ross,et al.  Everolimus: efficacy and safety in cardiac transplantation , 2010, Expert opinion on drug safety.

[22]  D. Granger,et al.  Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure. , 2010, Cardiovascular research.

[23]  C. Weber,et al.  Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. , 2010, Journal of molecular and cellular cardiology.

[24]  M. Gaestel,et al.  Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation , 2010, Journal of Cell Science.

[25]  A. Fernández,et al.  Preoperative statin treatment reduces systemic inflammatory response and myocardial damage in cardiac surgery. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[26]  S. Sindel,et al.  Effects of Everolimus on Cytokines, Oxidative Stress, and Renal Histology in Ischemia-Reperfusion Injury of the Kidney , 2009, Renal failure.

[27]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[28]  F. Schmitz,et al.  Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells , 2008, European journal of immunology.

[29]  A. Corsini,et al.  Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27Kip1/Cyclin E Expression , 2008, Molecular Pharmacology.

[30]  D. Teupser,et al.  Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. , 2008, Atherosclerosis.

[31]  Suzanne F. Jones,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Negrin,et al.  Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy , 2008, Cell cycle.

[33]  Sang Won Suh,et al.  Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. , 2007, The Journal of clinical investigation.

[34]  H. Gruber,et al.  Combined enzymatic and antioxidative treatment reduces ischemia-reperfusion injury in rabbit skeletal muscle. , 2006, The Journal of surgical research.

[35]  G. Dreyfus,et al.  Modulation of Systemic Inflammatory Response after Cardiac Surgery , 2005, Asian cardiovascular & thoracic annals.

[36]  Yuval Dor,et al.  Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. , 2005, Genes & development.

[37]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[38]  C. Ponticelli,et al.  The pleiotropic effects of mTor inhibitors. , 2004, Journal of nephrology.

[39]  M. Castresana,et al.  Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells. , 2004, The American surgeon.

[40]  Sarah L. Gaffen,et al.  The Interleukin (IL)‐2 Family Cytokines: Survival and Proliferation Signaling Pathways in T Lymphocytes , 2004, Immunological investigations.

[41]  C. Collard,et al.  The systemic inflammatory response to cardiopulmonary bypass. , 2003, Anesthesiology clinics of North America.

[42]  R. Virmani,et al.  Oral Everolimus Inhibits In-Stent Neointimal Growth , 2002, Circulation.

[43]  Schmucker,et al.  Perioperative serum levels of tumour‐necrosis‐factor alpha (TNF‐α), IL‐1β, IL‐6, IL‐10 and soluble IL‐2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution , 1999, Clinical and experimental immunology.

[44]  K. Nadeau,et al.  The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. , 1997, The Journal of clinical investigation.

[45]  B. Ryffel,et al.  Effect of rapamycin on the expression of the IL‐2 receptor (CD25) , 1996, Clinical and experimental immunology.

[46]  M. Janier,et al.  Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. , 1994, The American journal of physiology.

[47]  F. Mohr,et al.  Modern temperature management in aortic arch surgery: the dilemma of moderate hypothermia. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[48]  D. Fingar,et al.  Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. , 2012, The Biochemical journal.

[49]  K. Lehle,et al.  Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. , 2005, Transplantation proceedings.

[50]  M. Manns,et al.  Clinical Pharmacokinetics of Everolimus , 2004, Clinical pharmacokinetics.

[51]  D. Fairlie,et al.  Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. , 2004, The Journal of surgical research.

[52]  G. Lopaschuk,et al.  An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. , 1993, The Journal of pharmacology and experimental therapeutics.